Koji Ando

Koji Ando

Auto-generated profile, based on publicly available information

Koji Ando

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2024 in Nature Medicine
Verified
Journal Article
Open access
YNYoshiaki Nakamura
Yoshiaki Nakamura
JWJun Watanabe
Jun Watanabe
NANaoya Akazawa
Naoya Akazawa
KHKeiji Hirata
Keiji Hirata
KKKozo Kataoka
Kozo Kataoka
EOEIJI OKI
EIJI OKI
The interim analysis of the CIRCULATE-Japan GALAXY observational study demonstrated the association of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection with recurrence risk and benefit from adjuvant chemotherapy (ACT) in resectable colorectal cancer (CRC). This updated analysis with a 23-month median follow-up, including 2,240 patients with stage II-III colon cancer or stage IV CRC, reinforces the prognostic value of ctDNA positivity during the MRD window with significantly inferior disease-free survival (DFS; hazard ratio (HR): 11.99, P < 0.0001) and overall survival (OS; HR: 9.68, P < 0.0001). In patients who experienced recurrence, ctDNA positivity correlated with shorter OS (HR: 2.71, P < 0.0001). The significantly shorter DFS in MRD-positive patients was consistent across actionable biomarker subsets. Sustained ctDNA clearance in response to ACT was an indicator of favorable DFS and OS compared to transient clearance (24-month DFS: 89.0% versus 3.3%; 24-month OS: 100.0% versus 82.3%). True spontaneous clearance rate with no clinical recurrence was 1.9% (2/105). Overall, our findings provide evidence for the utility of ctDNA monitoring for post-resection recurrence and mortality risk stratification that could be used for guiding adjuvant therapy.

1 August 2015 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
TYTakafumi Yukaya
Takafumi Yukaya
HSHiroshi Saeki
Hiroshi Saeki
YKYuta Kasagi
Yuta Kasagi
YNYuichiro Nakashima
Yuichiro Nakashima
KAKoji Ando
Koji Ando
YMYoshihiko Maehara
Yoshihiko Maehara

5 June 2014 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
HKHiroyuki Kawano
Hiroyuki Kawano
HSHiroshi Saeki
Hiroshi Saeki
HKHiroyuki Kitao
Hiroyuki Kitao
YTYasuo Tsuda
Yasuo Tsuda
HOHajime Otsu
Hajime Otsu
YMYoshihiko Maehara
Yoshihiko Maehara

28 February 2012 in Surgery Today
Verified
Journal Article
Closed access
PDF file
MSMasahiko Sugiyama
Masahiko Sugiyama
MMMasaru Morita
Masaru Morita
RYRintaro Yoshida
Rintaro Yoshida
KAKoji Ando
Koji Ando
AEAkinori Egashira
Akinori Egashira
YMYoshihiko Maehara
Yoshihiko Maehara

30 October 2014 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
KAKoji Ando
Koji Ando
EOEIJI OKI
EIJI OKI
HSHiroshi Saeki
Hiroshi Saeki
ZYZhao Yan
Zhao Yan
YTYasuo Tsuda
Yasuo Tsuda
YMYoshihiko Maehara
Yoshihiko Maehara
Immunohistochemistry staining of p53 is a cheap and simple method to detect aberrant function of p53. However, there are some discrepancies between the result of immunohistochemistry staining and mutation analysis. This study attempted to find a new definition of p53 staining by its staining pattern. Immunohistochemistry staining of p53 and TP53 gene mutation analysis were performed in 148 gastric cancer patients. Also SNP‐CGH array analysis was conducted to four cases. Positive staining of p53 was observed in 88 (59.5%) tumors. Tumors with positive p53 staining showed malignant features compared to negative tumors. Mutation of TP53 gene was observed in 29 (19.6%) tumors with higher age and differentiated type. In positive p53 tumors, two types could be distinguished; aberrant type and scattered type. With comparison to TP53 gene mutation analysis, all the scattered type had wild‐type TP53 gene (P = 0.0003). SNP‐CGH array showed that scattered‐type tumors had no change in the structure of chromosome 17. P53‐scattered‐type staining tumors may reflect a functionally active nonmutated TP53 gene. In interpretation of p53 immunohistochemistry staining, distinguishing p53‐positive tumors by their staining pattern may be important in gastric cancer.

30 June 2009 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
EOEIJI OKI
EIJI OKI
YKYoshihiro Kakeji
Yoshihiro Kakeji
YZYan Zhao
Yan Zhao
RYRintaro Yoshida
Rintaro Yoshida
KAKoji Ando
Koji Ando
YMYoshihiko Maehara
Yoshihiko Maehara